Xu Fei, Zhang Li, Xiang Xiao-Juan, Wang Zhi-Qiang, Zhou Zhong-Mei, Wang Si-Yang
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Ai Zheng. 2006 Sep;25(9):1120-2.
BACKGROUND & OBJECTIVE: Anemia is a common complication of cancer patients. Recombinant human erythropoietin (rhEPO) can alleviate the symptoms of cancer-related anemia. However, the optimal use of rhEPO is still on investigation. This study was to find out the optimal use of rhEPO in anemic cancer patients undergoing chemotherapy.
From May, 2004 to Feb, 2005, 30 patients with cancer-related anemia receiving concurrent chemotherapy were enrolled. This open-labeled, non-randomized, and pilot study evaluated the response rate of induction rhEPO 120,000 U (40,000 U was subcutaneously injected on d1, 3, 5) followed by subcutaneous injection of maintenance dose of 40,000 U once a week for 3 weeks (d8, 15, 22). Hemoglobin (Hb) and hematocrit (Hct) were measured before treatment and fortnightly during the treatment.
Mean Hb maintained increasing during treatment. In week 2 (n=29) and week 4 (n=21), there were 27.59% and 61.90% patients, respectively, whose Hb value had increased more than 20 g/L from the baseline (79.56 g/L) and mean Hb were 90.26 g/L and 96.81 g/L respectively (P<0.05). And mean Hct at week 2 and week 4 were 27.01% and 30.17% respectively, which were higher than the baseline (24.29%)(P=0.062 and 0.001 respectively). All patients demonstrated fine tolerance.
Induction therapy followed by maintenance with rhEPO can improve the level of hemoglobin significantly and quickly in anemic cancer patients.
贫血是癌症患者常见的并发症。重组人促红细胞生成素（rhEPO）可缓解癌症相关性贫血的症状。然而，rhEPO的最佳使用方法仍在研究中。本研究旨在探寻rhEPO在接受化疗的贫血癌症患者中的最佳使用方法。
2004年5月至2005年2月，纳入30例接受同步化疗的癌症相关性贫血患者。本开放标签、非随机的前瞻性研究评估了诱导期使用rhEPO 120,000 U（第1、3、5天皮下注射40,000 U），随后每周皮下注射维持剂量40,000 U，共3周（第8、15、22天）的有效率。在治疗前及治疗期间每两周测量血红蛋白（Hb）和血细胞比容（Hct）。
治疗期间平均Hb持续上升。在第2周（n = 29）和第4周（n = 21），分别有27.59%和61.90%的患者Hb值较基线值（79.56 g/L）升高超过20 g/L，平均Hb分别为90.26 g/L和96.81 g/L（P < 0.05）。第2周和第4周的平均Hct分别为27.01%和30.17%，高于基线值（24.29%）（P分别为0.062和0.001）。所有患者耐受性良好。
rhEPO诱导治疗后维持治疗可显著且快速提高贫血癌症患者的血红蛋白水平。
